Please assess the completion status of the following clinical trial:

Trial Title: Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable heterosexual relationship~* History of erectile dysfunction for at least 6 months~* IIEF- EF Domain entry score (at Visit 2): \>21 points~* Documented metabolic syndrome according to the IDF (International Diabetes Foundation)~* Subjects motivated for erectile dysfunction treatment~* Documented, dated, written informed consent~Exclusion Criteria:~* Any underlying cardiovascular condition~* History of myocardial infarction~* Uncontrolled atrial fibrillation~* Resting hypotension~* Postural hypotension within 6 months of Visit 1~* History of congenital QT prolongation~* Bleeding disorder~* History of prostatectomy because of prostate cancer~* Hereditary degenerative retinal disorders~* History of loss of vision because of NAION (non-arteritic anterior ischemic optic neuropathy)~* 29 Additional Exclusion Criteria

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Vardenafil (Levitra, BAY38-9456) (Type: EXPERIMENTAL): Vardenafil 10 mg tablets PRN (pro re nata) for 4 weeks, Vardenafil 5 mg/10 mg/20 mg tablets PRN for consecutive 4 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets PRN (pro re nata) for 4 weeks, placebo tablets PRN for consecutive 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).